Comparison Between the Efficacy of SGLT2 Inhibitor Therapy Versus ACE Inhibitor in the Treatment of Diabetic Kidney Disease

NCT05373004 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

UNKNOWN

Status

212

Enrollment

OTHER_GOV

Sponsor class

Conditions

Diabetic Nephropathy Type 2

Interventions

DRUG: Empagliflozin 25 MG
DRUG: Enalapril Maleate 20 mg

Sponsor

Omar Tarek Elfarargi